Esperovax Awarded $1M for Development of an Oral COVID-19 RNA Vaccine under the HHS Project NextGen Initiative
03 Oct 2023
VaccinemRNAImmunotherapyClinical Study
PLYMOUTH, Mich., Oct. 3, 2023 /PRNewswire/ -- Esperovax, a U.S.-based preclinical biopharmaceutical company and a BLUE KNIGHT™ resident company, is receiving an award for $ 1 M to further develop a yeast-based oral COVID-19 RNA vaccine candidate as part of the BLUE KNIGHT™ QuickFire Challenge: Accelerating Project NextGen. This award will support critical studies aimed at demonstrating vaccine safety and immunoprotection in orally vaccinated animals challenged with different COVID-19 virus variants. Esperovax is collaborating with Dr. Slobodan Paessler at the University of Texas Medical Branch – Galveston to conduct these studies.
Blue Knight, a joint initiative between Johnson & Johnson Innovation – JLABS (JLABS) and the Biomedical Advanced Research and Development Authority (BARDA), collaborates with companies to accelerate innovation against emerging health security threats.
"This award enables animal challenge studies that may determine whether our unique oral COVID-19 RNA vaccine elicits protective immunity that prevents disease and reduces virus dissemination and affords completion of other requisite studies supportive of an Investigational New Drug application for future clinical evaluation," stated Dr. Robin Robinson, President and Chief Executive Officer. "Positive results from these studies have the potential to bring inexpensive, safe and long-lasting effective oral vaccines a step closer to address public health threats like COVID-19 and other emerging infectious diseases."
For more information, please visit our web site at www.esperovax.com
For those interested in learning more about the BLUE KNIGHT™ Resident QuickFire Challenge: Accelerating Project NextGen, visit https://jji.jnj/BK23.
SOURCE Esperovax
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.